nevirapine has been researched along with ritonavir in 151 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (10.60) | 18.2507 |
| 2000's | 55 (36.42) | 29.6817 |
| 2010's | 76 (50.33) | 24.3611 |
| 2020's | 4 (2.65) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| De Maeyer, M; Debyser, Z; Desadeleer, C; Hombrouck, A; Van Remoortel, B; Voet, A; Witvrouw, M | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, YC; Dumond, JB; Fiscus, SA; Horton, AL; Kashuba, AD; Patterson, KB; Rezk, NL; Tappouni, HL; Tien, HC; Vourvahis, M; Yeh, RF | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bagnoli, L; Desantis, J; Iraci, N; Marini, F; Mariotti, A; Pannecouque, C; Sancineto, L; Santi, C; Tabarrini, O | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Abadi, LF; Bhutani, KK; Desai, D; Gaikwad, S; Gupta, S; Kulkarni, S; Kumar, S; Singh, IP | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Gozlan, M | 1 |
| Hirschel, B; Rutschmann, O | 1 |
| Mueller, BU | 1 |
| Collins, DO; Sakamoto, A | 1 |
| Danner, SA; de Jong, MD; Koot, M; Lange, JM; Miedema, F; Pakker, NG; Reiss, P; Roos, MT; Schellekens, PT; van Leeuwen, R | 1 |
| Alaeus, A; Albert, J; Cox, S; Palmer, S | 1 |
| Danner, SA; de Wolf, F; Goudsmit, J; Hoetelmans, RM; Jurriaans, S; Lange, JM; Lukashov, VV; Notermans, DW; Prins, JM; Roos, M; Schuitemaker, H; Weverling, GJ | 1 |
| Saag, MS; Schooley, RT | 1 |
| Becker, M; Chesney, M; Deeks, SG; Grant, RM; Hellmann, NS; Parkin, NT; Petropoulos, CJ; Symonds, W; Volberding, PA | 1 |
| Berkhout, B; Boucher, CA; Keulen, W; Schuurman, R; van Wijk, A | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Arens, M; Heyden, NA; Pirounaki, M; Ratner, L | 1 |
| Butler, KM; Clarke, SM; Condon, S; Healy, CM; Mulcahy, F | 1 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Burger, DM; Hoetelmans, RM; Jurriaans, S; Lange, JM; Portegies, P; Prins, JM; Sommadossi, JP; Turner-Foisy, ML; van Praag, RM; Weverling, GJ; Zhou, XJ | 1 |
| Ahmed, PS; Bedard, J; Bowlin, TL; Chambers, P; Clarke, J; Kelly, LA; Rando, RF; Taylor, DL; Tyms, AS; Wood, LJ | 1 |
| Abrams, E; Aguayo, R; Bamji, M; Dieudonne, A; Jackson, JB; Johnson, G; Kovacs, A; Krogstad, P; Lee, S; McNamara, J; Mendez, H; Moye, J; Nachman, S; Rana, S; Sever, J; Stanley, K; Wiznia, A | 1 |
| Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R | 1 |
| Deray, G; Izzedine, H; Launay-Vacher, V | 1 |
| Doepel, L; Folkers, G | 1 |
| Cunningham, S; Eshleman, SH; Jackson, JB; Johnson, G; Krogstad, P; Lee, S; Nachman, S; Palumbo, P; Wang, YG; Wantman, M; Wei, LJ; Wiznia, A | 1 |
| Bartoli, A; Feroggio, M; Gianelli, L; Maserati, R; Montagna, M; Regazzi, MB; Villani, P | 1 |
| Bourin, M; Dailly, E; Jolliet, P; Kergueris, MF; Thomas, L | 1 |
| Burger, DM; Chesney, MA; Danner, SA; de Wolf, F; Hoetelmans, RM; Hugen, PW; Jambroes, M; Kauffmann, RH; Lange, JM; Meenhorst, PL; Nieuwkerk, PT; Schneider, MM; Schrey, G; Sprangers, MA; Sprenger, HG; van Der Ende, ME | 1 |
| Benson, CA; Brun, SC; Deeks, SG; Eron, JJ; Feinberg, J; Gulick, RM; Hicks, C; Hsu, A; Japour, AJ; Kempf, D; Kessler, HA; King, M; Murphy, RL; Real, K; Riddler, S; Sax, PE; Stryker, R; Sun, E; Thompson, M; Wheeler, D | 1 |
| Aguayo, R; Dieudonne, A; Jackson, JB; Johnson, G; Khoury, M; Krogstad, P; Lee, S; McNamara, J; Mendez, H; Moye, J; Nachman, S; Stanley, K; Wiznia, A | 1 |
| de Groot, R; Fraaij, PL; van Rossum, AM | 1 |
| Johnson, GM; Krogstad, PA; Lee, S; Mohan, K; Morse, EV; Nachman, S; Stanley, K; Van Dyke, RB; Wiznia, A | 1 |
| Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K | 1 |
| Jurriaans, S; Lange, JM; Weel, J; Weverling, GJ; Wit, FW | 1 |
| Gallant, JE | 1 |
| Fan, B; Stewart, JT | 1 |
| Burger, DM; Droste, JA; Verweij-Van Wissen, CP | 1 |
| Lackmann, GM; Niehues, T; Schmidt, B | 1 |
| Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, L; Nielsen, H; Obel, N; Pedersen, C | 1 |
| de la Cruz Pellín, M; Esteban, J; Gimeno, C; Mora, E | 1 |
| Aarnoutse, RE; Burger, DM; Prins, JM; van der Ende, ME | 1 |
| Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, LR; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Becker, S | 1 |
| Burger, D; Clotet, B; Côté, H; López, S; Martínez, E; Miró, O; Moltó, J; Montaner, J; Negredo, E; Puig, J; Rey-Joly, C; Ribalta, J; Ruiz, L; Salazar, J | 1 |
| Gerber, JG; Wyles, DL | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 1 |
| Acosta, EP; Aldrovandi, G; Chen, J; Damle, B; Hodge, J; Hughes, MD; King, JR; Nachman, S; Wiznia, A; Yogev, R | 1 |
| Baker, A; Crawford, W; Jassen, A; Jooste, JP; Van Zyl, AJ | 1 |
| Freedberg, KA; Holmes, CB; Martinson, NA; Walensky, RP; Zheng, H | 1 |
| Bourdet, DL; Brouwer, KL; Ho, RH; Kashuba, AD; Kim, RB; Leake, BF; Lowe, CM; McRae, MP; Tian, X | 1 |
| Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O | 1 |
| Aymard, G; Bergmann, JF; Mahé, I; Mouly, S; Rizzo-Padoin, N; Salvat, C; Simoneau, G; Verstuyft, C | 1 |
| DeJesus, E; Lou, Y; Masterman, A; Min, SS; Piliero, PJ; Shelton, MJ; Stein, DS; Summers, K; Wire, MB | 1 |
| Balfour, HH; Brundage, RC; Vezina, HE; Weller, DR | 1 |
| Choi, SO; Kashuba, AD; Rezk, NL | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F | 1 |
| Doerries, R; Drechsler, H; Gass, A; Hardmeier, M; Kuhle, J; Mehling, M; Ruegg, S | 1 |
| Bacchetti, P; Grunfeld, C; Heymsfield, S; Kotler, DP; Lee, G; Lewis, CE; Madden, E; Scherzer, R; Shlipak, MG; Tracy, R; Wanke, C | 1 |
| Fulco, PP; Higginson, RT; Zingone, MM | 1 |
| Roca, B | 1 |
| Boesmans, D; Di Fazio, V; Elens, L; Haufroid, V; Vanbinst, R; Veriter, S; Wallemacq, P | 1 |
| Allavena, C; Cahn, P; Clotet, B; Côté, H; Harris, M; Montaner, J; Negredo, E; Ochoa, C; Raffi, F; Singer, J; Thorne, A; Zala, C | 1 |
| Brinkman, K; Danner, SA; Geerlings, SE; Hassink, EA; Lips, P; Reiss, P; Ristola, M; Sutinen, J; van Agtmael, MA; van Vonderen, MG | 1 |
| De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Pozniak, A; Sekar, V; Vangeneugden, T | 1 |
| Alonso-Villaverde, C; Barrufet, P; Bonjoch, A; Clotet, B; Cucurull, J; Domingo, P; Estany, C; Force, L; Garrabou, G; Masabeu, A; Miró, O; Morén, C; Negredo, E; Pérez-Alvarez, N; Rodríguez-Santiago, B | 1 |
| Cedeño, S; Clotet, B; Deig, E; Maria Llibre, J; Miranda, C; Moltó, J; Negredo, E; Valero, S; Valle, M | 1 |
| Dickinson, L; Gibb, DM; Gilks, CF; Kayiwa, J; Khoo, S; Kityo, C; Lutwama, F; Munderi, P; Nalumenya, R; Reid, A; Ssali, F; Tumukunde, D; Walker, AS | 1 |
| Alston-Smith, B; Asmelash, A; Atwine, D; Chipato, T; Conradie, F; Currier, JS; Eshleman, S; Hakim, J; Hogg, E; Hosseinipour, MC; Hughes, MD; Kanyama, C; Lockman, S; McIntyre, J; Mellors, JW; Mngqibisa, R; Mohapi, L; Purcelle-Smith, E; Rahim, S; Rooney, J; Salata, RA; Sawe, F; Schooley, RT; Shaffer, D; Siika, A; Stringer, E; Walawander, A; Wools-Kaloustian, K; Zheng, Y | 1 |
| Abrams, EJ; Bobat, R; Bwakura-Dangarembizi, M; Chi, BH; Cotton, MF; Eshleman, SH; Hughes, MD; Jean-Philippe, P; Kamthunzi, P; Lindsey, JC; Meyers, T; Millar, L; Mofenson, LM; Musoke, P; Palumbo, P; Petzold, E; Purdue, L; Schimana, W; Violari, A | 1 |
| Boulle, A; Davies, MA; Egger, M; Eley, B; Giddy, J; Keiser, O; Moultrie, H; Rabie, H; Technau, K; Van Cutsem, G; Wood, R | 1 |
| Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Pau, AK; Somaroo, H | 1 |
| Chu, J; Ciaranello, AL; Conradie, F; Currier, J; Freedberg, KA; Holmes, CB; Hughes, M; Lockman, S; Losina, E; McIntyre, J; Pillay, S; Walensky, RP; Wood, R | 1 |
| Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Meyers, T; Morris, L; Sherman, G; Strehlau, R; Taylor, BS | 1 |
| Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S | 1 |
| Calis, JC; de Wit, TF; Geelen, SP; Sigaloff, KC; van Vugt, M | 1 |
| Nsanzabana, C; Rosenthal, PJ | 1 |
| Bhatti, L; Conner, C; Dejesus, E; Mills, A; Storfer, S | 1 |
| Hoffmann, C; Schewe, CK; Stellbrink, HJ; Weitner, L | 1 |
| Caro-Vega, Y; Crabtree-Ramírez, B; López-Martínez, A; O'Brien, NM; Sierra-Madero, J | 1 |
| Chipato, T; Cole, SR; Currier, JS; D'Amico, R; Eron, JJ; Hosseinipour, M; Hughes, MD; Lockman, S; McCarthy, JS; Meshnick, SR; Poole, C; Porter, KA; Salata, R; Sawe, FK; Shaffer, D; Siika, A; Skinner-Adams, TS; Stringer, E; Zheng, Y | 1 |
| McIntyre, J; Nachman, S | 1 |
| Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Persaud, D; Sherman, G; Strehlau, R; Tsai, WY | 1 |
| Butterworth, AS; Chipato, T; Currier, JS; D'Amico, R; Eron, JJ; Hosseinipour, MC; Lockman, S; McCarthy, JS; Meshnick, SR; Porter, KA; Salata, R; Sawe, F; Shaffer, D; Siika, A; Skinner-Adams, TS; Stringer, E | 1 |
| Abrams, EJ; Barlow-Mosha, L; Bobat, R; Chi, BH; Cotton, MF; Eshleman, SH; Hughes, MD; Jean-Philippe, P; Kamthunzi, P; Khadse, S; Lindsey, JC; Millar, L; Mofenson, LM; Moultrie, H; Mujuru, HA; Palumbo, P; Petzold, E; Purdue, L; Schimana, W; Violari, A | 1 |
| Alston-Smith, B; Amod, F; Asmelash, A; Chibowa, M; Chipato, T; Currier, J; Halvas, E; Hogg, E; Hosseinipour, M; Hughes, M; Kimaiyo, S; Lockman, S; McIntyre, J; Mellors, J; Mohapi, L; Rassool, M; Sawe, F; Schooley, R; Shaffer, D; Smith, L; Ssali, F; Zheng, Y | 1 |
| Jaye, A; Oko, F; Okomo, U; Peterson, I; Peterson, K; Togun, T; Townend, J | 1 |
| Cotton, M; Gibb, D; Penazzato, M; Prendergast, A; Tierney, J | 1 |
| Capeau, J; Danner, SA; Domingo, P; Feeney, ER; Mallon, PW; Reiss, P; van Agtmael, MA; van Vonderen, MG; Villarroya, F; Wit, F | 1 |
| Allavena, C; Bouquié, R; Dailly, E; Deslandes, G; Jolliet, P; Raffi, F | 1 |
| Abrams, EJ; Arpadi, S; Coovadia, A; Kuhn, L; Martens, L; Patel, F; Shiau, S; Strehlau, R | 1 |
| Hills-Nieminen, C; Tseng, A | 1 |
| Holmes, D | 1 |
| Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
| Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E | 1 |
| Achan, J; Ades, V; Aliba Luwedde, F; Clark, T; Cohan, D; Havlir, D; Kakuru, A; Kamya, M; Mwesigwa, J; Natureeba, P; Osterbauer, B; Plenty, A | 1 |
| Kawalec, P; Kryst, J; Mikrut, A; Pilc, A | 1 |
| Motsa, N; Mwanyumba, A; Perry, SH; Preidis, GA; Sarero, HN; Swamy, P | 1 |
| Currier, J; Hogg, E; Hosseinipour, M; Hughes, MD; Lockman, S; Mulenga, L; Mwafongo, A; Nkanaunena, K; Samaneka, W; Siika, A; Zheng, Y | 1 |
| Kuhn, L; Shiau, S | 1 |
| Abrams, EJ; Arpadi, SM; Coovadia, A; Kuhn, L; Martens, L; McIlleron, H; Meredith, S; Shiau, S; Strehlau, R; Wiesner, L | 1 |
| Benki-Nugent, S; Bunts, L; Casper, C; Huang, ML; John-Stewart, G; Richardson, B; Slyker, JA; Tapia, K; Wamalwa, D | 1 |
| Bao, Y; Currier, J; Hogg, E; Hughes, MD; Lockman, S; Moses, A; Sawe, F; Shaffer, D | 1 |
| Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW | 1 |
| Abrams, E; Muhe, LM; Penazzato, M; Prendergast, AJ; Tindyebwa, D | 1 |
| Asmelash, A; Currier, J; Hughes, MD; Kaloustian, KW; Lockman, S; Ogwu, A; Salata, R; Sawe, F; Shaffer, D; Zheng, Y | 1 |
| Clumeck, N; Delforge, M; Ilunga, J; Kabeya, K; Kadiebwe, D; Kapend, L; Kasamba, E; Matanda, S; Milolo, C; Mwamba, C; Necsoi, C; Vaira, D | 1 |
| Dooley, KE; Karlsson, MO; Svensson, EM | 1 |
| Benki-Nugent, S; Eshelman, C; John-Stewart, G; Langat, A; Okinyi, HM; Tapia, K; Wamalwa, D | 1 |
| Abrams, EJ; Barlow-Mosha, L; Bobat, R; Bwakura-Dangarembizi, M; Cotton, MF; Eshleman, SH; Hughes, MD; Jean-Philippe, P; Kamthunzi, P; Khadse, S; Lindsey, JC; Mofenson, LM; Moultrie, H; Palumbo, P; Petzold, E; Sambo, PM; Schimana, W; Violari, A; Zimmer, B | 1 |
| Ayaya, S; Ciaranello, AL; Doherty, K; Essajee, S; Freedberg, KA; Harrison, L; Kelly, K; Lindsey, JC; Losina, E; Muhe, L; Palumbo, P; Penazzato, M; Walensky, RP; Weinstein, MC; Wools-Kaloustian, K | 1 |
| Amogne, W; Assefa, G; Caulk, AW; Getenet, H; Gleason, RL; Parker, I; Seifu, D; Vidakovic, B | 1 |
| Barlow-Mosha, L; Cotton, M; Dominguez, K; Ford, N; Penazzato, M | 1 |
| Borderi, M; Calza, L; Colangeli, V; Conti, M; Magistrelli, E; Mancini, R; Viale, P | 1 |
| Blackman, BR; Collado, MS; Dash, A; Figler, RA; Lawson, MJ; Mackey, AJ; Manka, D; Marukian, S; Qualls, CW; Terelius, Y; Wamhoff, BR | 1 |
| Conradie, F; Hughes, J; Maartens, G; McIlleron, H; Pandie, M; Siwendu, S; Variava, E; Wiesner, L | 1 |
| Ferretti, F; Mora-Peris, B; Stevens, E; Taylor, S; Underwood, J; Winston, A | 1 |
| Angelidou, K; Archary, M; Barlow-Mosha, L; Barr, E; Chi, BH; Cotton, M; Dittmer, S; Fairlie, L; Jean-Phillipe, P; Kabugho, E; Kamthunzi, P; Kinikar, A; Lindsey, J; Mbengeranwa, T; Mofenson, L; Msuya, L; Palumbo, P; Patel, K; Sambo, P; Violari, A | 1 |
| Bonczkowski, P; Borch, A; De Scheerder, MA; De Spiegelaere, W; Koenig, R; Malatinkova, E; Melkova, Z; Vandekerckhove, L | 1 |
| Barlow-Mosha, L; Borkowsky, W; Chen, J; Chi, BH; Deygoo, N; Duffy, PE; Gabriel, EE; Hobbs, CV; Ilmet, T; Jean Philippe, P; Kamthunzi, P; Kirmse, B; Li, Y; Mofenson, L; Musoke, P; Neal, J; Palumbo, P; Parikh, S; Petzold, E; Prescott, W; Tauzie, J; Tegha, G | 1 |
| Alteri, C; Bernardi, S; Bertoli, A; Liuzzi, G; Manno, EC; Palma, P; Perno, CF; Rossi, P; Tchidjou, HK; Zangari, P | 1 |
| Brill, MJ; Karlsson, MO; Maartens, G; Pandie, M; Svensson, EM | 1 |
| Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Mbete, N; Murnane, PM; Patel, F; Shiau, S; Strehlau, R | 2 |
| Bon, I; Borderi, M; Bussini, L; Calza, L; Colangeli, V; Magistrelli, E; Re, MC; Viale, P | 1 |
| Canals, F; Gutiérrez, F; Masiá, M | 1 |
| Chimukangara, B; Katzenstein, D; Manasa, J; Masimirembwa, C; Mitchell, R; Nyabadza, G | 1 |
| de Mast, Q; Kinabo, GD; Mchaile, DN; Schellekens, AFA; Van de Wijer, L; van der Ven, AJAM | 1 |
| Brigante, G; Casarini, L; Diazzi, C; Guaraldi, G; Lania, AG; Lazzaretti, C; Potì, F; Prodam, F; Riccetti, L; Rochira, V; Rofrano, L; Sperduti, S | 1 |
| Chi, BH; Fairlie, L; Farhad, M; Fenton, T; Fowler, MG; Moodley, D; Naik, S; Nakabiito, C; Stringer, JSA; Venkatesh, KK | 1 |
| Abideen, G; Adeniji, H; Adeuja, O; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, AA; Busari, AW; Hassan, OO; Ken-Owotor, C; Kogbe, S; Ogunfowokan, T; Onwujuobi, AG; Oreagba, IA; Owolabi, ET; Usman, SO | 1 |
| Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K | 1 |
| Gill, MM; Herrera, N; Maile, L; Masenyetse, L; Masitha, M; Mokone, M; Tukei, VJ | 1 |
15 review(s) available for nevirapine and ritonavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1997 |
Antiviral chemotherapy.
Topics: Adult; Antiviral Agents; Child; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Protease Inhibitors; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine | 1997 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir | 2002 |
Pharmacogenomics of antiretrovirals.
Topics: Alkynes; Anti-Retroviral Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Dideoxynucleosides; Drug Hypersensitivity; Drug Resistance, Viral; Dyslipidemias; Genetic Predisposition to Disease; Genetic Testing; Glucuronosyltransferase; HLA Antigens; Humans; Hyperbilirubinemia; Nevirapine; Oligopeptides; Oxidoreductases, N-Demethylating; Patents as Topic; Patient Selection; Pharmacogenetics; Pyridines; Ritonavir | 2008 |
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Drug Resistance, Viral; Female; Health Resources; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Latin America; Lopinavir; Male; Mutation; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2011 |
Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combinations; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Ritonavir | 2012 |
Drug interactions between antiretrovirals and hormonal contraceptives.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Drug Interactions; Female; HIV Seropositivity; Humans; Medroxyprogesterone Acetate; Nevirapine; Pregnancy; Pregnancy, Unplanned; Protease Inhibitors; Ritonavir | 2013 |
Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome | 2013 |
Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.
Topics: Age Factors; Anti-HIV Agents; Clinical Protocols; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Ritonavir; Time Factors | 2014 |
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combinations; HIV Infections; Humans; Induction Chemotherapy; Infant; Infectious Disease Transmission, Vertical; Lopinavir; Maintenance Chemotherapy; Nevirapine; Ritonavir | 2014 |
Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
Topics: Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Nevirapine; Post-Exposure Prophylaxis; Pregnancy; Prospective Studies; Randomized Controlled Trials as Topic; Ritonavir; Zidovudine | 2015 |
Developments in early diagnosis and therapy of HIV infection in newborns.
Topics: Anti-HIV Agents; Early Diagnosis; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapine; Ritonavir; Zidovudine | 2018 |
50 trial(s) available for nevirapine and ritonavir
| Article | Year |
|---|---|
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
Topics: Adult; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Nelfinavir; Nevirapine; Phenotype; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir | 1999 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clin
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Ethnicity; Female; HIV Infections; Humans; Infant; Male; Nelfinavir; Nevirapine; Puerto Rico; Racial Groups; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; United States; Viral Load | 2000 |
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mutation; Nelfinavir; Nevirapine; Prospective Studies; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Failure; Viral Load | 2001 |
Viramune cleared for use in combination with protease inhibitors.
Topics: Adult; Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nevirapine; Ritonavir; Saquinavir; United States; United States Food and Drug Administration | 1998 |
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Mutation; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Treatment Failure; Viral Load | 2001 |
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome | 2002 |
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine | 2002 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Administration Schedule; Humans; Lamivudine; Nelfinavir; Nevirapine; Patient Compliance; Ritonavir; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 2002 |
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lactates; Male; Middle Aged; Nelfinavir; Nervous System Diseases; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Treatment Outcome | 2003 |
A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir | 2003 |
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cholesterol, LDL; Drug Tolerance; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Lopinavir; Male; Middle Aged; Mitochondria; Nevirapine; Prospective Studies; Pyrimidinones; Ritonavir; Safety | 2005 |
Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Outcome | 2005 |
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2006 |
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 2009 |
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Osteoporosis; Pyrimidinones; Ritonavir; Young Adult; Zidovudine | 2009 |
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.
Topics: Adult; Cross-Over Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome | 2009 |
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; DNA, Mitochondrial; Drug Therapy, Combination; Electron Transport Complex IV; Extremities; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipids; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2009 |
Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Pilot Projects; Pyridines; Ritonavir | 2010 |
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
Topics: Adult; Aged; Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Uganda | 2010 |
Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.
Topics: Africa, Eastern; Africa, Southern; Africa, Western; Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Clinical Protocols; Cohort Studies; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Mothers; Nevirapine; Pregnancy; Pyrimidinones; Research Design; Ritonavir; Zidovudine | 2011 |
Antiretroviral therapies in women after single-dose nevirapine exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Kaplan-Meier Estimate; Linear Models; Lopinavir; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Ritonavir; Statistics, Nonparametric; Tenofovir; Treatment Failure; Young Adult | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Kaplan-Meier Estimate; Lopinavir; Male; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Failure | 2010 |
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemias; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipid Metabolism; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphorus Compounds; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2011 |
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Lopinavir; Malaria; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
Topics: Alanine Transaminase; Anti-HIV Agents; Body Height; Body Weight; Chi-Square Distribution; Child, Preschool; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Male; Medication Adherence; Nevirapine; Ritonavir; Statistics, Nonparametric; Time Factors; Viral Load | 2012 |
The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Malaria; Nevirapine; Ritonavir | 2012 |
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
Topics: Anti-Retroviral Agents; CD4 Lymphocyte Count; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Lopinavir; Male; Nevirapine; Ritonavir; RNA, Viral; Zidovudine | 2012 |
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
Topics: Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; Death; Drug Resistance, Viral; Endpoint Determination; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Lopinavir; Medication Adherence; Mutation; Nevirapine; Ritonavir | 2012 |
Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; Gambia; HIV Infections; HIV-1; HIV-2; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Lopinavir; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Atrophy; CD4 Lymphocyte Count; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; HIV Seropositivity; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Subcutaneous Fat; Treatment Outcome; Young Adult; Zidovudine | 2012 |
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Drug Synergism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
Topics: Anti-HIV Agents; Body Composition; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Infant; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Nevirapine; Ritonavir; South Africa; Stavudine | 2013 |
WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Eruptions; Drug Substitution; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Ritonavir; Uganda; World Health Organization | 2013 |
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kidney Diseases; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2014 |
Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Nevirapine; Ritonavir; Sex Factors; South Africa; Treatment Outcome | 2014 |
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Pressure; Body Mass Index; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Cholesterol, HDL; Cholesterol, LDL; Deoxycytidine; Emtricitabine; Endpoint Determination; Female; HIV Infections; HIV-1; Humans; Linear Models; Logistic Models; Lopinavir; Multivariate Analysis; Nevirapine; Organophosphonates; Prospective Studies; Risk Factors; Ritonavir; RNA, Viral; Tenofovir; Triglycerides | 2014 |
Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children.
Topics: Antimalarials; Artemisinins; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Malaria; Male; Nevirapine; Parasitemia; Quinolines; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Uganda | 2014 |
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.
Topics: Adenine; Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Nevirapine; Organophosphonates; Ritonavir; Tenofovir; Treatment Outcome | 2014 |
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mycobacterium tuberculosis; Nevirapine; Ritonavir; Tuberculosis; Young Adult | 2014 |
Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child Development; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Kenya; Lopinavir; Male; Nevirapine; Ritonavir | 2015 |
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
Topics: Africa South of the Sahara; Anti-HIV Agents; Child, Preschool; Female; HIV Infections; HIV-1; Humans; Incidence; India; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lopinavir; Male; Nevirapine; Ritonavir; Treatment Outcome | 2014 |
Evolution of changes in cognitive function after the initiation of antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cognition; Cognition Disorders; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Male; Middle Aged; Neuropsychological Tests; Nevirapine; Ritonavir; Young Adult | 2016 |
Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child, Preschool; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Male; Nevirapine; Ritonavir; Severity of Illness Index; Treatment Failure; Treatment Outcome; Viral Load | 2016 |
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.
Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Coinfection; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Malaria, Falciparum; Malawi; Male; Nevirapine; Plasmodium falciparum; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 2016 |
Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child, Preschool; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Infant; Lipids; Lopinavir; Male; Nevirapine; Ritonavir; RNA, Viral; Treatment Outcome | 2017 |
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Ultrasonography, Prenatal; Young Adult; Zidovudine | 2019 |
86 other study(ies) available for nevirapine and ritonavir
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
Topics: Cell Line; Drug Resistance, Viral; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Naphthyridines; Quinolones; Virus Replication | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amniotic Fluid; Anti-HIV Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Fetal Blood; Genitalia, Female; HIV-1; Humans; Hydrocortisone; Pregnancy; Pregnancy Complications, Infectious; RNA, Viral | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.
Topics: Anti-HIV Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Glutamic Acid; Glycine; HIV-1; Humans; Isoleucine; Molecular Docking Simulation; Molecular Dynamics Simulation; Organoselenium Compounds; Simian Immunodeficiency Virus; Structure-Activity Relationship | 2015 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
Topics: Anti-HIV Agents; Blood-Brain Barrier; Cell Survival; Drug Design; HeLa Cells; HIV Reverse Transcriptase; Humans; Molecular Docking Simulation; Molecular Structure; Protein Binding; Pyrazoles; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2019 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Update on HIV transmission and pathogenesis.
Topics: Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; Disease Models, Animal; Genes, env; HIV; HIV Infections; HIV Protease Inhibitors; HIV-1; HLA-A Antigens; HLA-DR Antigens; HLA-DR Serological Subtypes; Humans; Macaca; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Simian Immunodeficiency Virus; Thiazoles; Time Factors; Valine; Virulence; Virus Latency; Virus Replication | 1995 |
More new drugs for HIV and associated infections.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytomegalovirus Retinitis; Cytosine; HIV Infections; Humans; Isoquinolines; Nelfinavir; Nevirapine; Organophosphonates; Organophosphorus Compounds; Protease Inhibitors; Pyridines; Ritonavir; Sulfonic Acids | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; HIV-1; Humans; Nevirapine; Ritonavir; RNA, Viral; T-Lymphocytes; Zidovudine | 1997 |
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 1998 |
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Virus Replication; Zidovudine | 1998 |
Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential.
Topics: Codon; Drug Resistance, Microbial; Evolution, Molecular; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Lamivudine; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir | 1999 |
Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line.
Topics: Anti-HIV Agents; beta-Galactosidase; Cell Line; Drug Resistance, Microbial; Genes, Reporter; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nevirapine; Phenotype; Receptors, CCR5; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 2000 |
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Outcome; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome; Zidovudine | 2000 |
Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Disease Reservoirs; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Semen; Stavudine; Viral Load; Zidovudine | 2000 |
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Drug Combinations; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Molecular Structure; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; T-Lymphocytes; Thionucleosides; Zidovudine | 2000 |
Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; HIV Protease Inhibitors; HIV-1; Humans; Kidney Failure, Chronic; Male; Nevirapine; Peritoneal Dialysis, Continuous Ambulatory; Ritonavir | 2001 |
Viracept combination studies.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Humans; Indinavir; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine | 1998 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Delavirdine; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Nevirapine; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid e
Topics: Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Nevirapine; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides | 2001 |
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Female; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Nevirapine; Odds Ratio; Patient Compliance; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Surveys and Questionnaires | 2001 |
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Cohort Studies; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Liver Function Tests; Male; Nevirapine; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Sex Factors; Transaminases | 2002 |
Antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Drug Administration Schedule; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Pyrimidinones; Ritonavir; Viral Load; Zidovudine | 2000 |
Determinations of zidovudine/didanosine/nevirapine and zidovudine/didanosine/ritonavir in human serum by micellar electrokinetic chromatography.
Topics: Anti-HIV Agents; Chromatography, Micellar Electrokinetic Capillary; Didanosine; Humans; Nevirapine; Ritonavir; Zidovudine | 2002 |
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Chromatography, High Pressure Liquid; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 2003 |
[Exanthema simulating measles without measles virus? Allergic reaction to a non-nucleoside reverse transcriptase inhibitor in an HIV infected boy treated with HAART].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Eruptions; Exanthema; Follow-Up Studies; HIV Infections; Humans; Infant; Male; Measles; Nevirapine; Recurrence; Reverse Transcriptase Inhibitors; Ritonavir | 2003 |
[Interaction between methadone and antiretrovirals (stavudine, indinavir, ritonavir, nevirapine)].
Topics: Anti-HIV Agents; Drug Interactions; Female; Humans; Indinavir; Male; Methadone; Narcotics; Nevirapine; Ritonavir; Stavudine; Substance Withdrawal Syndrome | 2003 |
The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID.
Topics: Drug Interactions; HIV Protease Inhibitors; Humans; Indinavir; Nevirapine; Ritonavir | 2004 |
Liver toxicity in epidemiological cohorts.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cohort Studies; Humans; Multivariate Analysis; Nevirapine; Ritonavir | 2004 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Hepatitis; HIV Infections; Humans; Indinavir; Liver Function Tests; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
Antiretroviral treatment in the Northern Cape.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Nevirapine; Oxazines; Pyrimidinones; Ritonavir; South Africa; Stavudine; Viral Load | 2005 |
Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
Topics: Adult; Anti-HIV Agents; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Female; HIV Infections; Humans; Lopinavir; Models, Biological; Nevirapine; Pyrimidinones; Ritonavir; South Africa | 2006 |
Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Benzoxazines; Biological Transport; Cells, Cultured; Child; Cyclopropanes; Hepatocytes; Humans; Male; Middle Aged; Nevirapine; Organic Anion Transporters; Organic Anion Transporters, Sodium-Dependent; Oxazines; Rats; Ritonavir; Saquinavir; Symporters; Taurocholic Acid | 2006 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2006 |
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breath Tests; Cohort Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Erythromycin; Female; HIV Infections; Humans; Indinavir; Liver; Male; Nelfinavir; Nevirapine; Ritonavir; Sex Factors | 2006 |
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet; Sulfonamides | 2007 |
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Structure; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Time Factors | 2007 |
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Lopinavir; Male; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Ritonavir; Severity of Illness Index | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; France; Furans; HIV Infections; Humans; Male; Models, Biological; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2008 |
Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.
Topics: Adenine; Adult; AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Didanosine; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Seizures; Stavudine; Tenofovir; Viral Load; Virus Replication; Zidovudine | 2008 |
Association of antiretroviral therapy with fibrinogen levels in HIV-infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Case-Control Studies; Cyclopropanes; Female; Fibrinogen; HIV Infections; Humans; Indinavir; Linear Models; Male; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir | 2008 |
Possible antiretroviral therapy-warfarin drug interaction.
Topics: Adult; Anticoagulants; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Interactions; Humans; Lopinavir; Middle Aged; Nelfinavir; Nevirapine; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Warfarin | 2008 |
Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Solid Phase Extraction; Sulfonamides | 2009 |
Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Monitoring; Female; HIV Infections; Humans; Infant; Male; Nevirapine; Pregnancy; Ritonavir; Salvage Therapy; South Africa; Treatment Failure; Viral Load | 2011 |
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Clinical Trials, Phase II as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Pyrimidinones; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; RNA, Viral; South Africa; Young Adult | 2011 |
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Life Expectancy; Lopinavir; Male; Nevirapine; Pregnancy; Pyrimidinones; Ritonavir; South Africa; Treatment Outcome | 2011 |
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.
Topics: Amino Acid Substitution; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Male; Mutation, Missense; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Ritonavir; RNA, Viral; Sequence Analysis, DNA; South Africa; Viral Load | 2011 |
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides | 2011 |
Resistance data in the ARTEN trial.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Female; HIV Infections; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir | 2011 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Epidemiologic Methods; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Mexico; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Nevirapine-based therapy after suppression: can we switch?
Topics: Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Nevirapine; Ritonavir | 2012 |
Talk of HIV cure goes viral.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child, Preschool; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Nevirapine; Primary Prevention; Ritonavir; Secondary Prevention; Time Factors; Zidovudine | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Darunavir; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver; Male; Nevirapine; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Drug Interactions; Eswatini; Female; HIV Infections; Humans; Lopinavir; Middle Aged; Nevirapine; Pregnancy; Pregnancy, Unplanned; Ritonavir; Young Adult | 2014 |
Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Epstein-Barr Virus Infections; HIV Infections; Humans; Infant; Kenya; Lopinavir; Nevirapine; Risk Factors; Ritonavir | 2014 |
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Clinical Trials as Topic; Cost-Benefit Analysis; Health Care Costs; HIV Infections; Humans; Infant; Infant, Newborn; Life Expectancy; Lopinavir; Male; Nevirapine; Ritonavir; South Africa | 2015 |
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
Topics: Adult; Alkynes; Anti-HIV Agents; Atherosclerosis; Benzoxazines; Biomarkers; Blood Pressure; C-Reactive Protein; Carotid Intima-Media Thickness; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Ethiopia; Female; Heart Rate; HIV Infections; HIV-1; Humans; Lipodystrophy; Lopinavir; Male; Middle Aged; Nevirapine; Pulse Wave Analysis; Ritonavir; Triglycerides | 2015 |
Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study.
Topics: Adult; Anti-HIV Agents; Bone Density; Cohort Studies; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Pilot Projects; Raltegravir Potassium; Ritonavir | 2016 |
Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes.
Topics: Anti-HIV Agents; Cell Culture Techniques; Cells, Cultured; Chemical and Drug Induced Liver Injury; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Nevirapine; Ritonavir; Transcriptome | 2016 |
Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Combinations; Drug Interactions; Drug Monitoring; Female; HIV Infections; Humans; Lopinavir; Male; Nevirapine; Ritonavir; Time Factors; Tuberculosis, Multidrug-Resistant; Young Adult | 2016 |
Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models.
Topics: Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; DNA, Viral; Genes, Reporter; Green Fluorescent Proteins; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lymphocyte Activation; Models, Biological; Nevirapine; Primary Cell Culture; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Viral Proteins; Virus Integration; Virus Latency; Virus Replication | 2016 |
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Nevirapine; Phylogeny; Ritonavir; Zidovudine | 2016 |
Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antitubercular Agents; Diarylquinolines; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Ritonavir; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
Topics: Adult; Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cholesterol, LDL; Cohort Studies; Drug Substitution; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Male; Middle Aged; Nevirapine; Prospective Studies; Raltegravir Potassium; Ritonavir; Rosuvastatin Calcium; Viral Load; Viremia | 2017 |
Community Based Antiretroviral Treatment in Rural Zimbabwe.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Community Health Centers; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Ritonavir; Rural Population; Treatment Failure; Viral Load; Young Adult; Zimbabwe | 2017 |
Safety Evaluation of Efavirenz in Children: Don't Forget the Central Nervous System.
Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nervous System; Nevirapine; Ritonavir | 2018 |
Reply to Van de Wijer et al.
Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; HIV; Humans; Lopinavir; Nevirapine; Ritonavir | 2018 |
Abacavir, nevirapine, and ritonavir modulate intracellular calcium levels without affecting GHRH-mediated growth hormone secretion in somatotropic cells in vitro.
Topics: Anti-Retroviral Agents; Calcium; Cell Line; Cell Survival; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Dideoxynucleosides; Growth Hormone-Releasing Hormone; Human Growth Hormone; Humans; Nevirapine; Phosphorylation; Ritonavir; Somatotrophs; Transfection | 2019 |
Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Malaria; Male; Middle Aged; Nevirapine; Nigeria; Ritonavir; Treatment Outcome; Young Adult | 2020 |
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Fluorenes; HIV Infections; Humans; Lopinavir; Lumefantrine; Malaria; Malaria, Falciparum; Nevirapine; Ritonavir; Uganda | 2023 |
Optimizing antiretroviral therapy for children living with HIV: Experience from an observational cohort in Lesotho.
Topics: Anti-HIV Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Lesotho; Lopinavir; Male; Nevirapine; Retrospective Studies; Ritonavir; Viral Load | 2023 |